Vertical: CNMBase Year: 2025
Market Size (2025)
$255.21M
Projected (2032)
$375.49M
CAGR (2022–2032)
5.7%
Key Players
12+
Market Overview
Direct-fed microbials (DFMs) are live, naturally occurring microorganisms, chiefly spore-forming Bacillus species, lactic acid bacteria and live yeasts, that are added to the feed or drinking water of livestock to support a stable and beneficial gastrointestinal microbiota. They are used to improve nutrient digestibility, feed conversion and resilience against enteric pathogens, and they have become a central tool for producers who are reducing or eliminating the routine use of antibiotics in animal production.
The Global Direct-Fed Microbials Market was valued at USD 255.21 Million in 2025, up from USD 216.22 Million in 2022. The market is projected to reach USD 375.49 Million by 2032, registering a CAGR of 5.67% over 2026–2032. This represents an absolute increase of USD 120.28 Million between 2025 and 2032. Growth is underpinned by tightening restrictions on antimicrobial use in feed, the continued expansion of poultry and pig production in Asia Pacific and Latin America, and a steady flow of new strains, formulations and regulatory authorisations from leading suppliers.
Key Findings
By Microorganism Type: Bacillus was the largest segment in 2025 at USD 114.84 Million (45.00% share), while Bacillus is the fastest-growing segment with a CAGR of 6.25% over 2026–2032.
By Livestock: Poultry was the largest segment in 2025 at USD 114.84 Million (45.00% share), while Others is the fastest-growing segment with a CAGR of 6.28% over 2026–2032.
By Physical Form: Dry was the largest segment in 2025 at USD 216.93 Million (85.00% share), while Liquid is the fastest-growing segment with a CAGR of 6.62% over 2026–2032.
By Region: Asia Pacific led the market in 2025 with USD 81.67 Million (32.00% share). Middle East & Africa is the fastest-growing region, with a CAGR of 6.90%.
By Country: The U.S. was the leading country market in 2025 at USD 41.55 Million. India is the fastest-growing country, expanding at a CAGR of 7.76% over 2026–2032.
Segmentation Summary
The market is analysed by microorganism type, livestock, physical form and region. By microorganism type, Bacillus accounted for USD 114.84 Million in 2025 and is expected to reach USD 175.72 Million by 2032, reflecting the heat and storage stability of spore-forming strains in pelleted feed. Lactic Acid Bacteria contributed USD 89.32 Million, with particularly strong positions in Europe and in ruminant and young-animal applications. By livestock, Poultry is the dominant application at USD 114.84 Million, followed by Swine (USD 63.80 Million) and Ruminants (USD 51.04 Million). By physical form, Dry products held 85.00% of the market in 2025, while Liquid formulations, used mainly through drinking-water and on-farm application systems, are growing faster at a CAGR of 6.62%.
Competitive Landscape Summary
The market is moderately consolidated at the top and fragmented below it. A small group of biosolutions and animal nutrition companies, led by Novonesis, dsm-firmenich, IFF (Danisco Animal Nutrition & Health) and Evonik, combines proprietary strain libraries, regulatory dossiers in major jurisdictions and global distribution. Specialist suppliers such as Kemin Industries, Lallemand Animal Nutrition, Phileo by Lesaffre and Church & Dwight (Arm & Hammer Animal and Food Production) compete on strain-specific evidence and technical service, while integrated feed and ingredient groups including Cargill, ADM, Alltech and Novus International address the category through yeast-based products, specialty ingredient portfolios and feed-mill networks. Recent years have seen significant structural change, notably the creation of Novonesis in January 2024, its acquisition of dsm-firmenich's share of the Feed Enzyme Alliance in June 2025, and dsm-firmenich's February 2026 agreement to sell its Animal Nutrition & Health business to CVC Capital Partners.
Challenges and Opportunities
The principal challenges are the cost and duration of strain-by-strain regulatory authorisation, variability of on-farm responses across diets, management systems and disease pressures, and price sensitivity among integrators in emerging markets, where DFMs compete with organic acids, phytogenics, enzymes and yeast-derived postbiotics for the same feed additive budget. Viability losses during pelleting and storage also remain a technical constraint for non-spore-forming organisms.
Opportunities are concentrated in three areas: the expansion of antibiotic-free poultry and pig production in Asia Pacific, Latin America and the Middle East & Africa; the development of ruminant-specific Bacillus and yeast products; and liquid and drinking-water formats that allow targeted application during stress periods such as placement, weaning and transport. Combination products that pair DFMs with enzymes or postbiotics, together with data-driven, farm-specific strain selection, offer suppliers routes to differentiation and premium pricing.
Future Outlook
Between 2025 and 2032 the market is expected to add USD 120.28 Million, with Asia Pacific contributing the largest absolute increase (USD 46.40 Million) and Middle East & Africa recording the highest growth rate. Bacillus is expected to strengthen its leading position, with its share rising from 45.00% in 2025 to 46.80% in 2032. Over the forecast period, competitive advantage is likely to depend on documented strain efficacy, regulatory coverage across multiple jurisdictions and the ability to offer integrated gut-health programmes rather than single products. Continued consolidation and ownership change among the leading suppliers are expected to reshape distribution and portfolio strategies through the end of the forecast period.
The Direct-Fed Microbials Market market is projected to grow at a CAGR of 5.7% from 2022 to 2032.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansDefinition
Direct-fed microbials are feed products that contain a source of live, naturally occurring microorganisms which, when fed to animals in adequate numbers, beneficially influence the composition and activity of the gastrointestinal microbiota. In regulatory terms they are classed in the United States as DFM products under U.S. Food and Drug Administration (FDA) policy, and in the European Union mainly as zootechnical feed additives in the functional group of gut flora stabilisers authorised under Regulation (EC) No 1831/2003. Their modes of action include competitive exclusion of pathogens, production of organic acids, bacteriocins and enzymes, modulation of the gut immune response and improvement of intestinal barrier function.
Included in the scope of this study:
Live bacterial cultures, including spore-forming Bacillus species (for example B. subtilis, B. licheniformis, B. amyloliquefaciens/velezensis) and lactic acid bacteria (for example Lactobacillus, Pediococcus, Enterococcus and Bifidobacterium strains)
Other live microorganisms used as DFMs, including live yeasts such as Saccharomyces cerevisiae and other bacterial or fungal cultures, reported under the Others microorganism type
Single-strain, multi-strain and combination products (for example DFM-enzyme complexes) supplied in dry or liquid physical form for poultry, swine, ruminants and other animals
Excluded from the scope of this study:
Prebiotics, yeast cell-wall fractions and inactivated or heat-killed microbial products (postbiotics), unless sold as part of a product whose primary active ingredient is a live microorganism
Feed enzymes, organic acids, essential oils and phytogenic additives sold as stand-alone products
Silage inoculants applied to forage rather than fed directly, and probiotics intended for human consumption
Scope of the Study
This study covers the Global Direct-Fed Microbials Market from 2022 to 2032. Market values are presented in USD Million for the historic years 2022–2024, the base year 2025 and the forecast period 2026–2032. The market is segmented by microorganism type, livestock and physical form, and analysed across five regions and their constituent country markets.
Research Objectives
To estimate the size of the Global Direct-Fed Microbials Market for 2022–2025 and forecast it for 2026–2032 in USD Million
To analyse the market by microorganism type (Bacillus, Lactic Acid Bacteria, Others) and identify the organisms gaining share as antibiotic growth promoters are phased out
To assess demand by livestock category (Poultry, Swine, Ruminants, Others) and the production trends that shape DFM adoption in each
To evaluate the relative position and growth of dry and liquid physical forms, including the role of drinking-water application
To quantify regional and country-level demand across North America, Europe, Asia Pacific, Latin America and Middle East & Africa
To examine the drivers, restraints, opportunities, regulatory frameworks and value-chain structure that influence the market
To profile the competitive environment, including the positioning, capabilities and recent strategic developments of leading DFM suppliers
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansOverview of the Research Process
The study followed a structured, multi-stage research process designed to produce consistent and verifiable market estimates. The process began with a definition of the market and its segmentation, followed by extensive secondary research to build an understanding of the product landscape, livestock production base, regulatory environment and competitive structure. Primary research with participants across the value chain was then used to validate assumptions, refine segment splits and test the forecast logic. Market sizing combined top-down and bottom-up approaches, and the results were reconciled through data triangulation before final review.
Stage 1: Market definition and segmentation framework
Stage 2: Secondary research and data collection
Stage 3: Primary research and expert validation
Stage 4: Market size estimation (top-down and bottom-up)
Stage 5: Data triangulation and forecasting
Stage 6: Quality review and final report preparation
Secondary Research
Secondary research established the baseline for market sizing and qualitative analysis. Sources were selected for their relevance to animal production, feed additives and microbial products:
Industry associations: feed manufacturing and feed additive associations such as the International Feed Industry Federation (IFIF), the European Feed Manufacturers' Federation (FEFAC), the American Feed Industry Association (AFIA) and national feed and poultry associations
Government and regulatory bodies: the U.S. FDA Center for Veterinary Medicine, the U.S. Department of Agriculture, the European Food Safety Authority (EFSA) and the European Commission's register of authorised feed additives, the Canadian Food Inspection Agency, China's Ministry of Agriculture and Rural Affairs, Brazil's Ministry of Agriculture and Livestock and India's Department of Animal Husbandry and Dairying
International organisations: livestock production, feed and trade statistics published by the Food and Agriculture Organization of the United Nations (FAO) and the World Organisation for Animal Health (WOAH)
Company filings: annual reports, investor presentations, product literature and press releases of DFM manufacturers, feed additive suppliers and integrated feed companies
Trade journals and scientific literature: animal nutrition and feed industry publications, peer-reviewed studies on probiotic efficacy and EFSA FEEDAP Panel scientific opinions
Paid databases: company financial databases, trade statistics and industry news archives
Primary Research
Primary research was conducted through in-depth telephone and online interviews with participants on both the supply side and the demand side of the market. Its objectives were to validate the market definition and segmentation, confirm the relative size of segments and regions, understand pricing and purchasing behaviour, and gather forward-looking views on demand, regulation and technology.
Supply-side respondents included product managers, technical and R&D managers, regulatory affairs specialists and regional sales heads at DFM manufacturers, feed additive companies, premix producers and distributors.
Demand-side respondents included nutritionists and purchasing managers at integrated poultry and pork producers, compound feed manufacturers, dairy and beef operations, veterinarians and academic animal science specialists.
Market Size Estimation
Top-down approach: The total feed additives and eubiotics market was used as a starting point and narrowed to direct-fed microbials using penetration and share assumptions derived from secondary research and validated through interviews. The resulting total was allocated to microorganism types, livestock categories, physical forms, regions and countries.
Bottom-up approach: Country-level demand was estimated from livestock populations and production volumes, compound feed output, DFM inclusion rates, the share of feed treated with DFMs and average selling prices. Country estimates were aggregated to regional and global totals. Revenue information from leading suppliers was used as a cross-check where available.
Data triangulation: Results from the two approaches were compared and reconciled. Where they differed, assumptions were re-examined against primary research inputs until a consistent estimate was reached for each segment, region and country.
Forecasting Methodology
Forecasts for 2026–2032 were developed by projecting the base-year estimates using a combination of trend analysis and factor-based adjustment. The factors considered include:
Projected growth in poultry, pig, cattle and aquaculture production by country
Compound feed production trends and feed price movements
Regulatory developments affecting antibiotic use and feed additive authorisation
Penetration of DFMs in antibiotic-free and reduced-antibiotic production systems
Product innovation, new strain approvals and the shift toward liquid and combination products
Macroeconomic conditions, including GDP growth, consumer spending on animal protein and currency movements
Each factor was assigned an expected direction and strength of impact for the short, medium and long term. The results were reviewed by industry participants before being finalised.
Base Year, Forecast Period and Currency
Base year: 2025
Historic years: 2022, 2023 and 2024
Forecast period: 2026–2032
CAGR period: 2026–2032
Currency: all values are presented in USD Million
Assumptions and Limitations
Market values are expressed at manufacturer selling price level and in nominal USD terms.
Livestock production in all regions is assumed to follow its current structural trajectory, without major disruption from animal disease outbreaks beyond historical norms.
Existing regulatory restrictions on antibiotic use in feed are assumed to remain in place or tighten further across all major markets during the forecast period.
Exchange rates are assumed to remain broadly stable over the forecast period.
Many DFM suppliers are privately held or report animal probiotics within broader business segments, so supplier-level revenues for this category are rarely disclosed and segment allocations rely on modelled estimates.
Products that combine live microorganisms with other active ingredients are allocated according to their primary live microbial component, which may differ from the classification used by individual companies.
Base Year
2025
Historical Period
2022 – 2024
Forecast Period
2026 – 2032
Primary Interviews
150+
Historical data (2022–2025) and forecast period (2025–2032)
Our research process spans primary interviews with industry stakeholders combined with comprehensive secondary data analysis, validated through triangulation across multiple independent sources.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansIntroduction
The Global Direct-Fed Microbials Market is moderately consolidated. A small number of global biosolutions and animal nutrition companies hold leading positions on the strength of proprietary strain libraries, multi-jurisdiction regulatory approvals, fermentation capacity and worldwide distribution. Below this tier, the market is fragmented, with specialist probiotic suppliers, yeast companies, integrated feed groups and a large number of regional manufacturers, particularly Bacillus producers in China and India, competing on price, local service and registrations.
Competition centres on documented efficacy for specific species and challenges, the breadth of regulatory authorisations, product stability in feed processing, and the quality of technical support offered to integrators and feed mills. Strategic activity since 2022 has been dominated by mergers, acquisitions and portfolio changes, species and market extensions of existing strains, and the launch of combination and waterline products.
Key Player Positioning
Market Leaders
Novonesis (Denmark): Formed in January 2024 through the combination of Novozymes and Chr. Hansen, Novonesis reported net sales of EUR 4,157.6 million in FY2025. It has one of the broadest DFM portfolios in the industry, including GalliPro (poultry), BioPlus (swine and ruminants), Bovamine and Bovacillus (cattle), and it strengthened its feed position by acquiring dsm-firmenich's share of the Feed Enzyme Alliance in June 2025.
dsm-firmenich (Switzerland/Netherlands): Its Animal Nutrition & Health business, which reported sales of EUR 3,269 million in FY2025, offers eubiotic products derived from the former Biomin portfolio, including PoultryStar and CYLACTIN. In February 2026, dsm-firmenich agreed to sell the business to CVC Capital Partners; the transaction had not been reported as closed at the time of writing.
IFF (United States): Through Danisco Animal Nutrition & Health, part of its Health & Biosciences segment (FY2025 segment sales of USD 2.28 billion; group net sales of USD 10.89 billion), IFF supplies Enviva PRO, Enviva DUO and the Syncra enzyme-probiotic range for poultry and swine.
Evonik (Germany): Evonik's Animal Nutrition business line, with FY2025 sales of EUR 1,944 million, markets Bacillus-based probiotics including Ecobiol, GutCare and GutPlus, produced at its plant in León, Spain, and has a joint venture in China with Shandong Vland Biotech.
Challengers
Kemin Industries (United States): A privately held specialty ingredients company whose CLOSTAT (Bacillus PB6) is one of the most widely used poultry DFMs; it has expanded through the ENTEROSURE multi-strain product and acquisitions of Bactana (2025) and CJ Youtell (2025).
Lallemand Animal Nutrition (Canada): The animal nutrition division of privately held Lallemand Inc. is the leading specialist in live yeast DFMs (LEVUCELL SC, LEVUCELL SB) and also supplies the LAB probiotic BACTOCELL; it acquired BIO-CAT in July 2026.
Phileo by Lesaffre (France): The animal care business of the Lesaffre Group (group turnover of EUR 3.2 billion in 2025) supplies ACTISAF live yeast probiotics and gained EU authorisation for its Bacillus-based MICROSAF in December 2025.
Church & Dwight, Arm & Hammer Animal and Food Production (United States): Part of the Specialty Products Division (FY2025 net sales of USD 299.0 million), it offers CERTILLUS Bacillus-based targeted microbial solutions supported by farm-level pathogen profiling.
Niche and Adjacent Players
Cargill (United States): With FY2026 revenue of USD 164 billion, Cargill participates in the gut-health category mainly through Diamond V yeast fermentation products and its global feed and premix network.
ADM (United States): ADM (FY2025 revenues of USD 80.27 billion; Nutrition segment revenue of USD 7,512 million) offers microbial feed products such as EMPIRA PRO and Citristim and is building animal microbiome research capability, while focusing its animal nutrition business on premix and specialty ingredients.
Alltech (United States): A privately held company built on yeast fermentation, offering YEA-SACC and the bacterial-yeast product LACTO-SACC, with a large feed-milling footprint through the Akralos joint venture with ADM.
Novus International (United States): Owned by Mitsui & Co. and Nippon Soda, Novus offers the SPORULIN Bacillus product for poultry and is developing swine microbials in partnership with Resilient Biotics.
Competitor Dashboard
The dashboard below compares the profiled companies on four qualitative parameters relevant to competitiveness in the DFM market.
Threat of New Entrants: Medium
Strain-by-strain regulatory approval requires significant time, data and investment, particularly in the European Union.
Established suppliers hold proprietary strain libraries, efficacy data and long-standing integrator relationships.
Regional fermentation companies in China and India continue to enter local markets with lower-cost products.
Bargaining Power of Suppliers: Low
Fermentation inputs such as sugars, proteins and carriers are widely available commodities.
Leading DFM producers own their strains and fermentation capacity and are often vertically integrated.
Bargaining Power of Buyers: High
Large integrators and feed manufacturers buy in volume and can switch between suppliers and additive categories.
Buyers increasingly demand on-farm trial data and return-on-investment evidence before adopting products.
Price sensitivity is high in emerging markets and during periods of weak producer margins.
Threat of Substitutes: Medium
Organic acids, phytogenics, enzymes, yeast-derived postbiotics and prebiotics address similar gut-health objectives.
These products are frequently used alongside DFMs rather than instead of them, which limits direct substitution.
Intensity of Competitive Rivalry: High
Multinational biosolutions companies and specialist suppliers compete on strain efficacy, regulatory coverage and technical service.
Product launches, species extensions and acquisitions are frequent.
Ongoing consolidation is creating larger, more integrated competitors.
Threat of New Entrants: Medium; Strain-by-strain regulatory approval requires significant time, data and investment, particularly in the European Union.
Bargaining Power of Suppliers: Low; Fermentation inputs such as sugars, proteins and carriers are widely available commodities.
Bargaining Power of Buyers: High; Large integrators and feed manufacturers buy in volume and can switch between suppliers and additive categories.
Threat of Substitutes: Medium; Organic acids, phytogenics, enzymes, yeast-derived postbiotics and prebiotics address similar gut-health objectives.
Intensity of Competitive Rivalry: High; Multinational biosolutions companies and specialist suppliers compete on strain efficacy, regulatory coverage and technical service.
Market estimates by geography (2032)
InsightAsia Pacific leads with $128.07M by 2032, while Middle East & Africa is projected to grow fastest at a 7.0% CAGR.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription Plans| REGION | 2022 | 2025 | 2032 | CAGR | SHARE |
|---|---|---|---|---|---|
| North America | $48.68M | $61.78M | $78.66M | 4.9% | 21% |
| Europe | $62.74M | $78.02M | $97.63M | 4.5% | 26% |
| Asia Pacific | $66.92M | $93.06M | $128.07M | 6.7% | 34% |
| Latin America | $27.53M | $37.51M | $50.74M | 6.3% | 14% |
| Middle East & Africa | $10.36M | $14.63M | $20.39M | 7.0% | 5% |
| Total | $216.22M | $285.00M | $375.49M | 5.7% | 100% |
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansTotal Market Size
$375.49M
| APPLICATION | REVENUE ($B) | GROWTH RATE | MARKET PENETRATION |
|---|---|---|---|
| Bacillus | $175.72M | 6.3% | 47% |
| Lactic Acid Bacteria | $129.99M | 5.5% | 35% |
| Others | $69.77M | 4.5% | 19% |
* Revenue projections based on 2025 estimates. Growth rates represent CAGR 2024–2030. Market penetration indicates current adoption rate within addressable market segments.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSee plans for professionals or small and medium businesses.
Analytical insights on Direct-Fed Microbials Market covering market dynamics, competitive landscape, and strategic outlook.
The Direct-Fed Microbials Market market is projected to reach $375.49M by 2032, growing at 5.7% CAGR. The Bacillus segment holds the largest share.
The Global Direct-Fed Microbials Market is shaped by a combination of regulatory, economic and technological forces. The removal of antibiotics from routine feed use is the most important structural driver, but demand for affordable animal protein, cost pressure on producers and steady progress in strain science are equally important in determining how quickly DFMs are adopted. Against these drivers, the cost of regulatory approval, inconsistent field results and competition from other gut-health additives act as restraints. Together, these forces support a market CAGR of 5.67% over 2026–2032.
Market Growth Factor Analysis
The table below summarises five macro factors and five micro factors that influence the market. For each factor, the impact type indicates whether it promotes, inhibits or has a steady effect on growth, and the impact score (out of 10) reflects its relative strength in three forecast windows. The scores are analyst assessments based on secondary research and interviews with industry participants, and are intended to show relative importance rather than precise measurement.
Regulatory Restrictions on Antibiotic Use in Feed
The progressive withdrawal of antibiotics from routine use in animal feed is the single most important driver of DFM demand. The European Union banned antibiotics as growth promoters from 1 January 2006 under Regulation (EC) No 1831/2003, and Regulation (EU) 2019/6 on veterinary medicinal products, applicable since January 2022, further restricts the preventive use of antimicrobials. In the United States, FDA Guidance for Industry #213 ended growth-promotion uses of medically important antimicrobials in January 2017 and placed their feed use under veterinary oversight, while Guidance #263 required the remaining over-the-counter medically important antimicrobials to move to prescription status, a transition completed in June 2023. China's Ministry of Agriculture and Rural Affairs Announcement No. 194 ended the use of growth-promoting antibiotic feed additives from 2020, and India prohibited colistin in food-producing animals and feed supplements in 2019. Each of these measures removes a tool that producers relied on to manage gut health and performance, and DFMs, particularly Bacillus strains with documented activity against Clostridium perfringens and other enteric pathogens, have become one of the principal replacements in poultry and pig diets.
Expanding Demand for Animal Protein
Global consumption of meat, milk and eggs continues to rise with population growth, urbanisation and higher incomes, particularly in Asia, Latin America, the Middle East and Africa. Poultry is the main beneficiary because it offers the lowest cost per kilogram of protein, short production cycles and broad cultural acceptance, which explains why poultry is also the largest application for DFMs. As production intensifies, stocking densities and growth rates increase, and the gut-health challenges associated with intensive systems become more pronounced. Large integrated producers in Brazil, China, India, Southeast Asia and the Gulf states are investing in modern housing, feed mills and biosecurity, and they increasingly specify gut-health programmes that include DFMs as standard. Growth in commercial aquaculture and in the organised dairy sector adds further demand from species outside the traditional poultry and swine base. Because DFM use scales directly with the volume of compound feed produced, growth in livestock output translates closely into growth in DFM consumption.
Focus on Feed Efficiency and Production Economics
Feed is the largest single cost in poultry, pig and cattle production, so even small improvements in feed conversion have a material effect on producer margins. DFMs improve nutrient digestibility through the enzymes and metabolites they produce, help maintain intestinal integrity and reduce the subclinical losses that erode growth rates and uniformity. Periods of high grain and soybean meal prices, such as those seen in 2022, sharpened producer attention on additives that deliver a measurable return on investment. Suppliers have responded with trial programmes, return-on-investment calculators and on-farm diagnostic services that link product use to feed conversion, mortality and carcass yield. As integrators move toward data-driven nutrition, products with a strong evidence base for performance are gaining preference, which supports the adoption of well-documented commercial strains.
Advances in Strain Science and Industry Investment
Continued investment in strain discovery, fermentation capacity and formulation technology is widening the range and reliability of DFM products. Leading suppliers maintain large proprietary strain libraries and use genomic screening, in vitro gut models and challenge studies to select strains for specific pathogens and species. Formulation advances have improved the heat stability of products in pelleted feed, extended shelf life and made drinking-water application practical. Capacity investments illustrate the commitment of the industry: Evonik more than doubled capacity at its probiotics plant in León, Spain in 2023; Novonesis was formed in January 2024 through the combination of Novozymes and Chr. Hansen, bringing together enzyme and probiotic capabilities; and Lallemand completed its acquisition of BIO-CAT in July 2026, adding enzyme and microbial production in the United States. These investments are expanding product availability and supporting entry into new species and geographies.
Growth in Emerging Livestock Markets
Emerging regions offer the largest headroom for DFM adoption because current penetration remains below that of Europe and North America while livestock production is expanding quickly. Middle East & Africa is the fastest-growing region with a CAGR of 6.90% over 2026–2032, and Asia Pacific and Latin America are also projected to grow above the global average. Suppliers that build local registrations, technical service teams and distribution partnerships in these regions are well placed to capture this growth.
Ruminant, Aquaculture and Companion Animal Applications
Most DFM volume is used in poultry and swine, but the development of strains for ruminants and for aquaculture, equine and companion animals is widening the addressable market. The Others livestock segment is the fastest-growing at a CAGR of 6.28%. Recent examples include the European launch of Novonesis' Bovacillus, a Bacillus probiotic for dairy cows, in April 2026, and Lallemand's LEVUCELL Trivantage for cattle and horses in the United States in October 2025.
Liquid, Waterline and Combination Products
Liquid formulations are the fastest-growing physical form, with a CAGR of 6.62%. Drinking-water delivery allows producers to apply DFMs during specific risk periods and avoids the heat stress of pelleting. IFF launched Enviva DUO, a waterline DFM for poultry, in January 2025. Combination products that pair DFMs with enzymes or postbiotics, such as IFF's Syncra range and Lallemand's LEVUCELL Trivantage, offer further scope for premium positioning.
Cost and Duration of Regulatory Approval
DFMs are authorised strain by strain and, in many jurisdictions, species by species. In the European Union, each strain requires a dossier covering identity, safety for the target animal, consumer, user and environment, and efficacy, assessed by the EFSA FEEDAP Panel before authorisation, with renewals required every ten years. Comparable but separate procedures apply in China, Brazil, Canada and other markets. The cost and time involved favour large companies with established regulatory teams and limit the speed at which smaller suppliers can bring new strains to market or extend claims to additional species.
Variability of Field Results and Product Stability
The performance response to DFMs depends on diet composition, disease pressure, management standards and the baseline health of the flock or herd, so results in commercial settings can vary from those in controlled trials. This variability makes it harder for suppliers to demonstrate a consistent return on investment and can lead producers to remove products when feed budgets tighten. Non-spore-forming organisms such as many lactic acid bacteria are also sensitive to heat, moisture and oxygen, and viability can fall during pelleting and storage unless specialised coating or post-pellet application is used.
Price Sensitivity and Competing Additives
In price-sensitive markets, DFMs compete for the same feed additive budget as organic acids, essential oils and phytogenics, feed enzymes, yeast cell-wall products and postbiotics. Producers often combine several of these tools, but when margins are under pressure they tend to retain the lowest-cost options, which can limit the penetration of premium probiotic products.
Targeted and Data-Driven Microbial Solutions
Suppliers are moving from generic products toward strains selected for the pathogen profile of a specific farm or region. Church & Dwight's Arm & Hammer business uses farm-level pathogen profiling to match strains from its Bacillus library, and Cargill introduced Galleon, an AI-based platform for analysing livestock gut microbiome data, in 2025. This trend increases the value of diagnostic capability and strengthens customer relationships.
Consolidation and Portfolio Reshaping
The supplier base is undergoing significant structural change. The Novozymes and Chr. Hansen merger created Novonesis in January 2024, Novonesis acquired dsm-firmenich's share of the Feed Enzyme Alliance in June 2025, and dsm-firmenich agreed in February 2026 to sell its Animal Nutrition & Health business to CVC Capital Partners. These transactions are concentrating microbial and enzyme capabilities and are likely to change distribution arrangements in several markets.
Strain Stability and Next-Generation Spore Technology
Faster spore germination, improved pellet stability and multi-strain formulations are becoming key points of differentiation among Bacillus products. Evonik launched Ecobiol PRO in June 2026 with an improved manufacturing process designed to accelerate germination, and several suppliers are extending existing strains to additional species and delivery formats.
Challenge: Demonstrating Value and Defining Claims
DFM suppliers must demonstrate consistent economic value while operating within claim restrictions that separate feed products from veterinary medicines. In the United States, for example, DFM products are marketed as feeds rather than drugs, which limits the health claims that can be made. Clear communication of mode of action, robust trial data and transparent strain identification will remain important for maintaining producer confidence.
The DFM value chain runs from strain development and fermentation inputs through manufacturing and distribution to livestock producers. Value is concentrated in proprietary strains, regulatory dossiers and technical service, rather than in raw materials.
DFMs are regulated as feed additives or feed ingredients in all major markets, and authorisation is usually specific to the strain and the target species. The table below summarises the key frameworks by region.
The table below lists key launches, acquisitions, partnerships, approvals and expansions by the profiled companies from 2022 onward.
Jul 2022: Kemin Industries; Product Launch; Launched ENTEROSURE, a multi-strain Bacillus probiotic for poultry and livestock, globally.
Aug 2022: Church & Dwight (Arm & Hammer); Expansion; Opened The ScienceHearted Center in Waukesha, Wisconsin, to screen Bacillus strains for its CERTILLUS range.
Jan 2023: IFF; Regulatory Approval; Received Canadian Food Inspection Agency approval for Enviva PRO (poultry) and Syncra SWI (swine).
Jan 2023: Lallemand Animal Nutrition; Regulatory Approval; BACTOCELL authorised in the EU as a technological additive for all animal species.
Jan 2023: Phileo by Lesaffre; Product Launch; Launched ACTISAF Sc 47 HR+, a heat-resistant live yeast probiotic for pelleted poultry feed.
Feb 2023: Evonik; Expansion; More than doubled capacity at its probiotics plant in León, Spain.
Feb 2023: Church & Dwight (Arm & Hammer); Product Launch; Launched CERTILLUS Eco Dairy Bedding, a Bacillus-based bedding treatment for dairy farms.
Jan 2024: Novonesis; Merger; Completed the combination of Novozymes and Chr. Hansen, creating Novonesis.
Jan 2024: Evonik; Joint Venture; Evonik Vland Biotech, a joint venture with Shandong Vland Biotech focused on probiotics and gut health in China, began operations.
Feb 2024: Church & Dwight (Arm & Hammer); Product Launch; Launched CERTILLUS HatchWell and CERTILLUS MoveWell Bacillus products for poultry at IPPE 2024.
Mar 2024: Novus International; Acquisition; Acquired enzyme company BioResource International.
Jun 2024: IFF; Regulatory Approval; Received EU approval for the Syncra AVI enzyme-probiotic complex for poultry.
Jan 2025: Kemin Industries; Regulatory Approval; EU authorisation of CLOSTAT extended to all categories of pigs.
Jan 2025: IFF; Product Launch; Launched Enviva DUO, a waterline DFM for poultry, in the United States, India and Pakistan.
Jan 2025: Novus International; Partnership; Formed a development partnership with Resilient Biotics on swine microbials.
Mar 2025: IFF; Product Launch; Extended Enviva PRO to weaned piglets, with availability in the United States and Japan.
Mar 2025: Novonesis; Partnership; Expanded its distribution partnership with Robinson Bioproducts across Canada for products including GalliPro, BioPlus and Bovamine.
Apr 2025: Evonik; Product Launch; Launched Ecobiol in mainland China through its joint venture with Shandong Vland Biotech.
May 2025: Kemin Industries; Acquisition; Acquired Bactana, a developer of gut-health solutions for livestock and companion animals.
Jun 2025: Novonesis; Acquisition; Completed the acquisition of dsm-firmenich's share of the Feed Enzyme Alliance for EUR 1.5 billion.
Jul 2025: Phileo by Lesaffre; Investment; Lesaffre made a strategic investment in CanBiocin, a developer of species-specific probiotics.
Sep 2025: Kemin Industries; Acquisition; Acquired CJ Youtell Biotech, including fermentation plants in China.
Sep 2025: Alltech / ADM; Joint Venture; Agreed to form a North American feed joint venture, launched as Akralos in February 2026.
Oct 2025: Lallemand Animal Nutrition; Product Launch; Launched LEVUCELL Trivantage for dairy and beef cattle and horses in the United States.
Dec 2025: Phileo by Lesaffre; Regulatory Approval; MICROSAF, a three-strain Bacillus probiotic, authorised in the EU for fattening poultry.
Feb 2026: dsm-firmenich; Divestment; Agreed to sell its Animal Nutrition & Health business to CVC Capital Partners.
Apr 2026: Novonesis; Product Launch; Launched Bovacillus, a Bacillus probiotic for dairy cows, in the European Union.
Jun 2026: Evonik; Product Launch; Launched Ecobiol PRO, a faster-germinating Bacillus probiotic for poultry.
Jul 2026: Lallemand Animal Nutrition; Acquisition; Completed the acquisition of BIO-CAT, a U.S. producer of enzymes and microbials.
Political
Government action plans on antimicrobial resistance in the EU, United States, China, India and other countries are reducing antibiotic use in livestock and favour alternatives such as DFMs.
Trade policy and import regulations for feed additives affect market access, particularly where local registration is required for each strain.
Economic
Feed grain and protein meal prices influence producer margins and their willingness to invest in additives.
Rising incomes in emerging economies support growth in poultry, pork, dairy and aquaculture production.
Currency movements affect the cost of imported products in Latin America, Africa and parts of Asia.
Social
Consumer demand for meat and eggs produced without antibiotics is encouraging retailers and food service companies to set sourcing requirements.
Growing attention to animal welfare supports products that improve gut health and reduce mortality.
Technological
Genomic screening, in vitro gut models and microbiome analytics are accelerating strain selection.
Improved encapsulation, spore technology and liquid formulations are increasing stability and widening application methods.
Digital tools are linking product use to farm performance data.
Environmental
Better feed conversion reduces the feed, land and water used per unit of animal protein.
Lower nitrogen and phosphorus excretion through improved digestibility supports compliance with nutrient management rules.
Life-cycle assessments are increasingly used to quantify the carbon footprint benefits of feed additives.
Legal
Strain-specific authorisations, ten-year renewals in the EU and labelling rules govern market entry and claims.
Distinctions between feed additives and veterinary medicines limit the health claims that DFM suppliers can make.
Profiles of 108 companies operating in the Direct-Fed Microbials Market market, including revenue, employee count, and market positioning where available.
Showing 108 of 108 companies
Company Headquarters: Missouri, US Founded: 1991 Workforce: ~800+ Company Working: Novus International manufactures animal health and nutrition products for livestock, poultry, and aquaculture. The products offered by the company include various preservative premixtures, feed supplements, feed additives, nutritional feed acids, chelated trace minerals, feed preservatives, feed antioxidants, and other specialty ingredients. Under its eubiotics products category, the company offers ACIDOMIX, a uniquely formulated blend of organic acids which ensures delivery of its acidification to the lower digestive tract. In addition to its preserving effects, the product has antimicrobial effects that help reduce bacterial contamination levels and energy waste resulting in optimal growth rates. The company has research & development laboratories and manufacturing facilities in more than 35 countries, as well as offices with field staff in an additional 60 countries. Novus International operates as a subsidiary of Mitsui & Co. (U.S.A.) Inc. and Nippon Soda Co., Ltd.
4 interactive charts drawn from the Direct-Fed Microbials Market dataset — market size, regional splits and each segment breakdown. Open one to read its full data table and download it.
Global Direct-Fed Microbials Market By Physical Form
Global Direct-Fed Microbials Market By Livestock
Global Direct-Fed Microbials Market By Microorganism Type
Global Direct-Fed Microbials Market By Region
Powering the world's best teams.
From next-gen startups to established enterprises.
Trusted by forward-thinking businesses
for data-driven intelligence
Co-Founder, Mojave Rail Fabrication Limited
This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job.
Manager, JavolVision
Thanks, I am so happy that we worked together. Maybe we still can work together in the future.
Sales Operations & Pricing Manager, Intel
Thanks. It's been a pleasure working with you, please use me as reference with any other Intel employees.
Sales Leader, Bamberg
We bought your "2025 report" in 2020. Everything is fine and very good.
Account and Business Manager, EFS-Holland BV
Thanks for sending the report it gives us a good global view of the Betaïne market.
Senior Retail Manager, LG Chem
We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.
Management Consultant, Level 21
I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.
Group Product Manager HVAC & Fire Protection GMA, Rockwool
I have been reading the first document or the study, the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!
R&D Director, Seojin
Thanks for your great support. Appreciate it. Well received report. It helps us to understand market well. We're planning other area of survey in the future, let's keep in touch.
Strategy & Business Development Director, Dogan Holding
We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.
Historical performance and future projections (2020–2030, USD Billion)
Market Size (USD Million)
